BRASKEM SA-CLASS A- ADR (BAK) Fundamental Analysis & Valuation

NYSE:BAK • US1055321053

4.38 USD
-0.35 (-7.4%)
At close: Mar 13, 2026
4.38 USD
0 (0%)
After Hours: 3/13/2026, 4:04:05 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BAK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

BAK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 83 industry peers in the Chemicals industry. BAK may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, BAK is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. BAK Profitability Analysis

1.1 Basic Checks

  • BAK had negative earnings in the past year.
  • BAK had a negative operating cash flow in the past year.
  • In the past 5 years BAK reported 4 times negative net income.
  • Of the past 5 years BAK 4 years had a positive operating cash flow.
BAK Yearly Net Income VS EBIT VS OCF VS FCFBAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10B -10B 20B

1.2 Ratios

  • BAK's Return On Assets of -6.36% is on the low side compared to the rest of the industry. BAK is outperformed by 75.90% of its industry peers.
  • BAK has a worse Return On Invested Capital (0.56%) than 73.49% of its industry peers.
Industry RankSector Rank
ROA -6.36%
ROE N/A
ROIC 0.56%
ROA(3y)-5.51%
ROA(5y)-1.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BAK Yearly ROA, ROE, ROICBAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300

1.3 Margins

  • BAK has a worse Operating Margin (0.60%) than 77.11% of its industry peers.
  • BAK's Operating Margin has declined in the last couple of years.
  • BAK has a Gross Margin of 6.52%. This is amonst the worse of the industry: BAK underperforms 87.95% of its industry peers.
  • In the last couple of years the Gross Margin of BAK has declined.
Industry RankSector Rank
OM 0.6%
PM (TTM) N/A
GM 6.52%
OM growth 3Y-60.34%
OM growth 5Y-26.07%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-36.57%
GM growth 5Y-9.41%
BAK Yearly Profit, Operating, Gross MarginsBAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. BAK Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BAK is destroying value.
  • The number of shares outstanding for BAK remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for BAK remains at a similar level compared to 5 years ago.
  • BAK has a worse debt/assets ratio than last year.
BAK Yearly Shares OutstandingBAK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
BAK Yearly Total Debt VS Total AssetsBAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

  • Based on the Altman-Z score of 0.79, we must say that BAK is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of BAK (0.79) is worse than 79.52% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.79
ROIC/WACC0.1
WACC5.73%
BAK Yearly LT Debt VS Equity VS FCFBAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20B 40B 60B

2.3 Liquidity

  • A Current Ratio of 1.21 indicates that BAK should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.21, BAK is doing worse than 85.54% of the companies in the same industry.
  • A Quick Ratio of 0.68 indicates that BAK may have some problems paying its short term obligations.
  • BAK has a Quick ratio of 0.68. This is amonst the worse of the industry: BAK underperforms 85.54% of its industry peers.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 0.68
BAK Yearly Current Assets VS Current LiabilitesBAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BAK Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 26.92% over the past year.
  • BAK shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.70%.
  • The Revenue has been growing by 8.15% on average over the past years. This is quite good.
EPS 1Y (TTM)26.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92%
Revenue 1Y (TTM)9.7%
Revenue growth 3Y-9.84%
Revenue growth 5Y8.15%
Sales Q2Q%-18.65%

3.2 Future

  • BAK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.40% yearly.
  • The Revenue is expected to grow by 1.99% on average over the next years.
EPS Next Y84.98%
EPS Next 2Y29.71%
EPS Next 3Y24.4%
EPS Next 5YN/A
Revenue Next Year-7.33%
Revenue Next 2Y-1.17%
Revenue Next 3Y1.99%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BAK Yearly Revenue VS EstimatesBAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20B 40B 60B 80B 100B
BAK Yearly EPS VS EstimatesBAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 20 -20 40

More info and screens

Find the best growth stocksShow best growing peers

1

4. BAK Valuation Analysis

4.1 Price/Earnings Ratio

  • BAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BAK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BAK Price Earnings VS Forward Price EarningsBAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as BAK.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.9
BAK Per share dataBAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • BAK's earnings are expected to grow with 24.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.71%
EPS Next 3Y24.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BAK Dividend Analysis

5.1 Amount

  • BAK does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BAK Fundamentals: All Metrics, Ratios and Statistics

BRASKEM SA-CLASS A- ADR

NYSE:BAK (3/13/2026, 4:04:05 PM)

After market: 4.38 0 (0%)

4.38

-0.35 (-7.4%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)03-11
Earnings (Next)05-12
Inst Owners18.41%
Inst Owner Change-10.78%
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap1.75B
Revenue(TTM)77.41B
Net Income(TTM)-5.81B
Analysts49.33
Price Target4.67 (6.62%)
Short Float %4.35%
Short Ratio2.88
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)-61.09%
DP-0.02%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.08%
Min EPS beat(2)64.59%
Max EPS beat(2)89.58%
EPS beat(4)2
Avg EPS beat(4)-292.98%
Min EPS beat(4)-870.87%
Max EPS beat(4)89.58%
EPS beat(8)2
Avg EPS beat(8)-200.87%
EPS beat(12)3
Avg EPS beat(12)-141.89%
EPS beat(16)4
Avg EPS beat(16)-120.57%
Revenue beat(2)0
Avg Revenue beat(2)-9.32%
Min Revenue beat(2)-10.48%
Max Revenue beat(2)-8.16%
Revenue beat(4)0
Avg Revenue beat(4)-6.86%
Min Revenue beat(4)-10.48%
Max Revenue beat(4)-1.01%
Revenue beat(8)0
Avg Revenue beat(8)-4.75%
Revenue beat(12)1
Avg Revenue beat(12)-3.68%
Revenue beat(16)2
Avg Revenue beat(16)-3.02%
PT rev (1m)0%
PT rev (3m)0.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)19.67%
EPS NY rev (3m)20.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.55%
Revenue NY rev (3m)-0.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 13.9
EPS(TTM)-2.58
EYN/A
EPS(NY)-1.75
Fwd EYN/A
FCF(TTM)-2.8
FCFYN/A
OCF(TTM)-1.26
OCFYN/A
SpS37.79
BVpS-1.85
TBVpS-3.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -6.36%
ROE N/A
ROCE 0.71%
ROIC 0.56%
ROICexc 0.56%
ROICexgc 0.59%
OM 0.6%
PM (TTM) N/A
GM 6.52%
FCFM N/A
ROA(3y)-5.51%
ROA(5y)-1.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-67.54%
ROICexgc growth 5Y-28.26%
ROICexc growth 3Y-67.47%
ROICexc growth 5Y-28%
OM growth 3Y-60.34%
OM growth 5Y-26.07%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-36.57%
GM growth 5Y-9.41%
F-Score3
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 11.38
Cap/Depr 65.27%
Cap/Sales 4.08%
Interest Coverage 0.1
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 0.68
Altman-Z 0.79
F-Score3
WACC5.73%
ROIC/WACC0.1
Cap/Depr(3y)88.47%
Cap/Depr(5y)83.1%
Cap/Sales(3y)5.43%
Cap/Sales(5y)4.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92%
EPS Next Y84.98%
EPS Next 2Y29.71%
EPS Next 3Y24.4%
EPS Next 5YN/A
Revenue 1Y (TTM)9.7%
Revenue growth 3Y-9.84%
Revenue growth 5Y8.15%
Sales Q2Q%-18.65%
Revenue Next Year-7.33%
Revenue Next 2Y-1.17%
Revenue Next 3Y1.99%
Revenue Next 5YN/A
EBIT growth 1Y374.38%
EBIT growth 3Y-64.24%
EBIT growth 5Y-20.05%
EBIT Next Year190.02%
EBIT Next 3Y90.95%
EBIT Next 5YN/A
FCF growth 1Y-736.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-158.55%
OCF growth 3Y-45.19%
OCF growth 5Y1.46%

BRASKEM SA-CLASS A- ADR / BAK FAQ

What is the ChartMill fundamental rating of BRASKEM SA-CLASS A- ADR (BAK) stock?

ChartMill assigns a fundamental rating of 2 / 10 to BAK.


Can you provide the valuation status for BRASKEM SA-CLASS A- ADR?

ChartMill assigns a valuation rating of 1 / 10 to BRASKEM SA-CLASS A- ADR (BAK). This can be considered as Overvalued.


What is the profitability of BAK stock?

BRASKEM SA-CLASS A- ADR (BAK) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for BAK stock?

The Earnings per Share (EPS) of BRASKEM SA-CLASS A- ADR (BAK) is expected to grow by 84.98% in the next year.